Osiris Therapeutics

Osiris Therapeutics, Inc. was founded in 1992 based on stem cell technology discovered by researchers at Case Western Reserve University led by Dr. Arnold Caplan. He recognized this technology had tremendous therapeutic potential.
Today, more than two decades after the journey began, Osiris continues to advance the science of cellular regenerative medicine to treat patients in need. Osiris Therapeutics, based in Columbia, Maryland, is the world leader in researching, developing and marketing regenerative medicine products. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4™, Cartiform® and Grafix®. Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. BIO4 is a trademark of Stryker Corporation (NYSE: SYK).

Columbia, US
Size (employees)
211 (est)
Osiris Therapeutics was founded in 1992 and is headquartered in Columbia, US

Key People at Osiris Therapeutics

Linda Palczuk

Linda Palczuk

President and CEO
Philip R. Jacoby

Philip R. Jacoby


Osiris Therapeutics Office Locations

Osiris Therapeutics has an office in Columbia
Columbia, US (HQ)
7015 Albert Einstein Drive

Osiris Therapeutics Data and Metrics

Osiris Therapeutics Financial Metrics


Net income (FY, 2014)

(1.8 m)

EBIT (FY, 2014)

1.7 m

Market capitalization (20-Jul-2017)

235.7 m

Closing share price (20-Jul-2017)


Cash (31-Dec-2014)

2.2 m
Osiris Therapeutics's current market capitalization is $235.7 m.
USDFY, 2013FY, 2014

Operating expense total

20.5 m45 m


(2.8 m)1.7 m

Net Income

41.6 m(1.8 m)
USDFY, 2013FY, 2014


2.4 m2.2 m

Accounts Receivable

15.3 m10 m


355 k650 k

Current Assets

84.1 m95.9 m


1.9 m2.1 m

Total Assets

92.1 m98.1 m

Accounts Payable

4.8 m8.9 m

Current Liabilities

10.8 m10.6 m

Additional Paid-in Capital

282.7 m287.5 m

Retained Earnings

(201.8 m)(203.5 m)

Total Equity

80.9 m84 m

Financial Leverage

1.1 x1.2 x
USDFY, 2013FY, 2014

Depreciation and Amortization

587 k940 k

Accounts Receivable

(4.7 m)(18 m)


(651 k)(9 m)

Accounts Payable

(2.8 m)(57 k)

Cash From Operating Activities

(13.3 m)(3.1 m)

Purchases of PP&E

(528 k)(1.1 m)

Cash From Investing Activities

11.6 m1.1 m

Cash From Financing Activities

2.2 m1.9 m

Income Taxes Paid

539 k619 k
Y, 2014

Financial Leverage

1.2 x

Osiris Therapeutics Market Value History

Traffic Overview of Osiris Therapeutics

Osiris Therapeutics Company Life and Culture

You may also be interested in